A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis : Phase II
Articolo
Data di Pubblicazione:
2019
Citazione:
A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis : Phase II / G. Marseglia, A. Licari, S. Leonardi, M. Papale, A.M. Zicari, L. Schiavi, G. Ciprandi, F. Cardinale, S. Cherubini, P. Giordano, P. Marchisio, A. Martelli, D. Minasi, M. Miraglia Del Giudice, F. Paravati, G. Pellegrini, A. Podesta, L. Pogliani, C. Salpietro, M.A. Tosca, A. Verrotti. - In: THE ITALIAN JOURNAL OF PEDIATRICS. - ISSN 1720-8424. - 45:1(2019 Jul), pp. 84.1-84.6. [10.1186/s13052-019-0678-y]
Abstract:
Background: Lertal®, an oral nutraceutical, contains extract of Perilla, quercetin, and Vitamin D3. The current polycentric, randomized, parallel-group, controlled study aimed in the Phase II to evaluate the efficacy and safety of Lertal® in preventing allergic rhinitis (AR) exacerbations in children after the end of the pharmacological treatment phase. Materials and methods: One hundred twenty-eight children completed Phase II. Sixty-four children continued Lertal® treatment (Lertal® Group: LG) and 64 ones did not assume any medication (Observation Group: OG) for 4-12 weeks. The study endpoints were the number, intensity, and duration of AR exacerbations, and the length of symptom-free time. Results: Children of LG halved the risk (HR = 0.54) of having AR exacerbation. Children of LG had significantly (p = 0.039) less AR exacerbations than OG children. In children with AR exacerbations, the total number of days in which each patient took at least one rescue medication was significantly (p = 0.018) lesser in LG children than OG ones. In the global population, the cumulative days treated with rescue medication was significantly (p < 0.0001) higher in OG than in LG. There was no clinically relevant adverse event. Conclusions: The present study documented that prolonged Lertal® assumption was safe and able to significantly reduce, such as halving, the risk of AR exacerbation, their duration and the use of rescue medications, after the suspension of the one-month antihistamine treatment. Therefore, Lertal® could be envisaged as an effective preventive treatment in AR children able to guarantee long symptom-free time. Trial registration: Clinical trial registration: ClinicalTrials gov ID NCT03365648.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Allergic rhinoconjunctivitis; Exacerbation; Nutraceutical; Perilla frutescens; Preventive treatment; Quercetin; Vitamin D3
Elenco autori:
G. Marseglia, A. Licari, S. Leonardi, M. Papale, A.M. Zicari, L. Schiavi, G. Ciprandi, F. Cardinale, S. Cherubini, P. Giordano, P. Marchisio, A. Martelli, D. Minasi, M. Miraglia Del Giudice, F. Paravati, G. Pellegrini, A. Podesta, L. Pogliani, C. Salpietro, M.A. Tosca, A. Verrotti
Link alla scheda completa: